74 - Clinical and Microbiology Outcomes of Bloodstream Infections (BSI) in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HCT) in a Randomized, Double-blind, Placebo-controlled Cohort 2 of a Phase 1b Study of SER-155, an Investigational Live Biotherapeutic

Presenting Author(s)

• TA

  Tessa Andermann, MD, MPH (she/her/hers)

  Assistant Professor of Medicine
  University of North Carolina at Chapel Hill
  Chapel Hill, NC, United States

Co-Author(s)

• 

  David Fredricks, MD (he/him/his)

  Professor
  Fred Hutchinson Cancer Research Center; University of Washington
  Seattle, WA, United States
• BT

  Bina Tejura, MD

  Senior Medical Director
  Seres Therapeutics
  Cambridge, Massachusetts, United States
• DL

  David Lichter, ALM

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• BH

  Brooke Hasson, PhD

  Seres Therapeutics, Cambridge, MA
  Cambridge, Massachusetts, United States
• MC

  Meghan Chafee, PhD

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• NH

  Nathan Hicks, PhD

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• ML

  Mary-Jane Lombardo, PhD

  Seres Therapeutics, Inc
  Cambridge, Massachusetts, United States
• CF

  Christopher Ford, PhD (he/him/his)

  Vice President
  Seres Therapeutics, Inc
  Cambridge, Massachusetts, United States
• MH

  Matt Henn, PhD

  Chief Scientific Officer
  Seres Therapeutics, Inc.
  Cambridge, MA, United States
• DW

  Dennis M. Walling, MD MMCI

  Seres Therapeutics
  Cambridge, Massachusetts, United States